EYFP Antibody

What is EYFP and why are antibodies against it valuable in research?

EYFP (Enhanced Yellow Fluorescent Protein) is a genetic mutant of green fluorescent protein (GFP) originally derived from the jellyfish Aequorea victoria. It functions as an epitope tag for the detection of recombinant proteins and has an excitation peak at 514 nm and emission peak at 527 nm . EYFP antibodies are valuable because they allow researchers to detect EYFP-tagged fusion proteins in applications where the intrinsic fluorescence of EYFP may be insufficient, compromised by fixation, or when additional signal amplification is desired.

The major advantages of using EYFP antibodies include:

• Detection of low-abundance EYFP fusion proteins beyond direct fluorescence visualization

• Compatibility with multiple detection methodologies (Western blot, immunohistochemistry, immunofluorescence)

• Retention of signal after fixation procedures that might quench natural EYFP fluorescence

• Ability to amplify signal through secondary antibody detection systems

What GFP variants will an anti-EYFP antibody recognize?

Most commercially available EYFP antibodies demonstrate cross-reactivity with several GFP variants due to high sequence homology. According to multiple sources, anti-GFP antibodies typically recognize various fluorescent proteins in the GFP family:

• Native GFP and Enhanced GFP (EGFP)

• Yellow Fluorescent Protein (YFP) and Enhanced YFP (EYFP)

• Cyan Fluorescent Protein (CFP)

What are the recommended antibody dilutions for different applications?

Optimal antibody dilutions vary based on application method, antibody concentration, and target abundance. Based on the search results, here are typical dilution ranges for EYFP antibodies:

These values are general guidelines based on information from multiple antibody suppliers . It's strongly recommended to optimize dilutions for your specific experimental conditions, as protein expression levels, fixation methods, and detection systems can significantly impact antibody performance.

How should researchers validate EYFP antibodies for their experiments?

Proper antibody validation is essential for ensuring reproducible and reliable results. According to recent guidelines on antibody use in physiology research, validation should include:

• Positive controls: Use known sources that express EYFP, such as:

  • Cells transfected with EYFP expression vectors

  • Recombinant EYFP protein as a control sample

  • Tissues from transgenic animals expressing EYFP

• Negative controls:

  • Non-transfected cells or wild-type tissues

  • Samples where primary antibody is omitted (for immunohistochemistry)

  • Pre-incubation of the antibody with purified EYFP protein to block specific binding

• Application-specific validation:

  • For Western blotting: Verify band size corresponds to EYFP (approximately 27 kDa) or expected fusion protein size

  • For immunofluorescence: Compare antibody staining pattern with native EYFP fluorescence

  • For multiple applications: Validate antibody separately for each application

Remember that an antibody that works well for Western blotting may not necessarily work for immunohistochemistry due to differences in epitope accessibility and protein conformation .

What strategies can help ensure EYFP antibody specificity in complex samples?

Ensuring antibody specificity is critical for accurate experimental interpretation. Here are methodological strategies to enhance specificity:

• Validation with knockout/knockdown models:

  • Use CRISPR/Cas9-mediated knockout cell lines as negative controls

  • Compare signals between cells expressing and not expressing EYFP

• Epitope competition assays:

  • Pre-incubate antibody with excess purified EYFP protein

  • If binding is specific, this should eliminate or significantly reduce signal

• Multiple antibody approach:

  • Use antibodies targeting different epitopes of EYFP

  • Concordant results increase confidence in specificity

• Dilution optimization:

  • Titrate antibody concentrations to determine optimal signal-to-noise ratio

  • Too high concentration can increase non-specific binding

• Buffer optimization:

  • Include appropriate blocking agents (BSA, serum matched to secondary antibody source)

  • Add detergents at appropriate concentrations to reduce non-specific hydrophobic interactions

What are the key considerations for using EYFP antibodies in immunoblotting?

Successful immunoblotting with EYFP antibodies requires attention to several technical factors:

• Sample preparation:

  • Ensure complete protein denaturation (important since EYFP has a β-barrel structure)

  • Use appropriate lysis buffers that effectively solubilize membrane-bound EYFP fusion proteins

• Gel selection and transfer:

  • 10-12% gels are typically suitable for resolving EYFP (27 kDa)

  • For larger EYFP fusion proteins, adjust gel percentage accordingly

• Blocking and antibody incubation:

  • 5% non-fat milk or 3-5% BSA are typically effective for blocking

  • Include complete molecular weight markers on blots to accurately identify EYFP bands

• Data interpretation:

  • EYFP typically appears at approximately 27 kDa

  • For fusion proteins, calculate expected molecular weight by adding EYFP size (27 kDa) to your protein of interest

  • Multiple bands may indicate proteolytic cleavage or post-translational modifications of the fusion protein

• Quantification considerations:

  • Include proper loading controls

  • For comparing expression levels between samples, normalization is critical

How can researchers optimize immunofluorescence detection of EYFP-tagged proteins?

Optimizing immunofluorescence detection of EYFP-tagged proteins requires careful consideration of:

• Fixation protocol selection:

  • Paraformaldehyde (4%) is commonly used and preserves EYFP structure reasonably well

  • Be aware that some fixation methods may quench native EYFP fluorescence

• Antibody selection:

  • Choose antibodies validated specifically for immunofluorescence

  • Consider using anti-GFP antibodies that recognize EYFP with high affinity

• Signal optimization:

  • Implement appropriate antigen retrieval if necessary

  • Optimize antibody concentration through titration experiments

  • Use secondary antibodies with appropriate spectral properties that don't overlap with EYFP's own fluorescence

• Controls to include:

  • Samples with known EYFP expression patterns

  • No primary antibody control to assess background from secondary antibody

  • Comparison with native EYFP fluorescence to confirm specificity

• Counterstaining considerations:

  • Select nuclear or other counterstains with minimal spectral overlap with EYFP or secondary antibody fluorophores

How can EYFP antibodies be used for super-resolution imaging techniques?

Super-resolution imaging with EYFP antibodies can overcome the diffraction limit of light microscopy. Based on published research approaches:

• dSTORM (direct Stochastic Optical Reconstruction Microscopy) applications:

  • EYFP shows enhanced photostability in dSTORM buffer conditions (oxygen removal with addition of thiols)

  • A 6-fold enhancement in photostability has been demonstrated under these conditions

  • dSTORM buffer prohibits EYFP from entering long-lived reversible or irreversible dark states

• Buffer optimization for super-resolution:

  • Oxygen removal combined with β-mercaptoethanol significantly improves EYFP performance

  • This approach yields higher localization density and more complete structural information in cellular imaging

• Methodological considerations:

  • Anti-EYFP antibodies can be used with secondary antibodies conjugated to photoswitchable fluorophores

  • When using antibody-based detection, account for the linkage error introduced by primary and secondary antibody size (typically 10-20 nm)

• DNA origami nanorulers:

  • EYFP-DNA conjugates have been successfully used to create calibration standards for super-resolution microscopy

  • These provide precise distance measurements for validating and optimizing super-resolution techniques

What strategies are effective for studying protein dynamics using destabilized EYFP variants?

Destabilized EYFP variants provide valuable tools for studying dynamic gene expression and protein turnover:

• SsrA-mediated peptide tagging approach:

  • C-terminal fusion of SsrA peptide tags (ASV, AAV variants) creates destabilized EYFP variants

  • These variants show dramatically reduced half-lives compared to native EYFP:

    • eYFP-ASV: half-life of 22 ± 4 minutes

    • eYFP-AAV: half-life of 8 ± 3 minutes

    • Native eYFP: stable for >24 hours

• Experimental considerations:

  • Transcription inhibition with rifampicin and translation inhibition with tetracycline can be used to assess protein stability

  • Detection of destabilized variants requires higher sensitivity due to lower steady-state levels

  • Western blot analysis using anti-GFP antibodies (cross-reacting with EYFP) can be used to quantify turnover rates

• Advantages and limitations:

  • Advantages: Allows measurement of dynamic changes in gene expression with higher temporal resolution

  • Limitations: Lower reporter output (approximately twofold lower for eYFP-ASV) may present detection challenges for weakly expressed genes

• Application considerations:

  • Selection of appropriate variant depends on the dynamics of the process being studied

  • For rapidly changing systems, variants with shorter half-lives (AAV) are preferred

  • For more stable systems, variants with moderate stability (ASV) may provide better signal-to-noise ratio

How do EYFP antibodies perform with different fixation and embedding protocols for advanced microscopy?

The performance of EYFP antibodies varies considerably with different fixation and embedding protocols:

What factors should be considered when designing fluorescent fusion proteins with EYFP?

Designing effective fluorescent fusion proteins with EYFP requires careful consideration of several factors:

• Fusion position considerations:

  • N-terminal vs. C-terminal fusions affect protein localization and function differently

  • When a protein's functional domains are unknown, it's recommended to create both N- and C-terminal fusions to maximize the likelihood of retaining function

• Linker design:

  • Flexible linkers (typically glycine-serine repeats) help prevent steric hindrance

  • Optimal linker length depends on the specific protein but typically ranges from 5-15 amino acids

• Functional domain preservation:

  • Avoid disrupting known functional domains or targeting sequences

  • For example, with lumenal ER proteins containing signal sequences and KDEL retention motifs, EYFP should be placed internal to these critical sequences

• Validation approaches:

  • Compare localization of EYFP fusion to untagged protein (via immunofluorescence)

  • Assess functionality through appropriate functional assays

  • Compare expression levels relative to endogenous protein

• Color variant considerations:

  • Create multiple color variants of desired fusion proteins

  • GFP variant sequences are identical at NH₂- and COOH-termini, facilitating the use of the same PCR primers to amplify multiple variants simultaneously

How can researchers troubleshoot common issues with EYFP antibody detection?

Troubleshooting EYFP antibody detection requires systematic evaluation of potential issues:

• No signal or weak signal:

  • Possible causes: Low expression, inefficient protein transfer (for Western blots), inadequate permeabilization (for immunofluorescence), or antibody degradation

  • Solutions: Verify expression by checking native EYFP fluorescence, optimize transfer conditions, increase permeabilization time/strength, or use fresh antibody aliquots

• High background:

  • Possible causes: Insufficient blocking, too high antibody concentration, or non-specific binding

  • Solutions: Extend blocking time, titrate antibody concentration, add additional blocking agents (e.g., 0.1-0.5% Tween-20 in wash buffer)

• Multiple bands in Western blots:

  • Possible causes: Proteolytic degradation, cross-reactivity, or post-translational modifications

  • Solutions: Add protease inhibitors during sample preparation, verify specificity using knockout/knockdown controls, or analyze migration pattern to assess if bands represent known modifications

• Discrepancy between native fluorescence and antibody staining:

  • Possible causes: Conformation changes affecting epitope accessibility, fixation effects on EYFP structure

  • Solutions: Try different fixation methods, use alternative antibody clones, or consider live-cell imaging approaches

• Flow cytometry detection issues:

  • Possible causes: Inadequate cell permeabilization for intracellular EYFP, spectral overlap with other fluorophores

  • Solutions: Optimize permeabilization protocol, adjust compensation settings, or use appropriate fluorophore combinations to minimize spectral overlap

How can EYFP antibodies be utilized in COVID-19 research applications?

EYFP antibodies have found novel applications in COVID-19 research through fusion protein approaches:

• YFP-labeled spike receptor-binding domain (RBD) applications:

  • Constructs for expression and purification of YFP-labeled 2019-nCoV spike RBD have been developed

  • These fusion proteins are secreted from adherent cells into serum-free medium and purified using Ni-NTA immobilized metal ion affinity chromatography

• Experimental applications:

  • Binding studies on cells or in vitro

  • Fluorescent labeling of potential virus-binding sites on cells

  • Use as an antigen for immunization studies

  • Development of novel virus or antibody detection assays

• Technical considerations:

  • The fusion proteins are soluble and monodisperse as confirmed by size-exclusion chromatography

  • N-linked glycosylations are present in the secreted protein

  • Complex formation with human ACE2 (the receptor for the spike RBD) can be confirmed both for YFP-fused spike RBD and for spike RBD alone after proteolytic removal of YFP

• Methodological advantages:

  • The protocol involves only standard cell culture techniques and equipment

  • Expression by secretion into serum-free medium from stably transfected HEK293 cells enables efficient production

What emerging technologies are enhancing EYFP antibody applications in research?

Several emerging technologies are expanding the utility of EYFP antibodies in research:

• Hyperstable fluorescent protein variants:

  • Recently developed "hyperfolder YFP" (hfYFP) demonstrates remarkable stability under conditions that denature most biological structures

  • These variants withstand chaotropic conditions, are chloride insensitive, and tolerate harsh fixation methods better than conventional fluorescent proteins

• DNA origami nanorulers:

  • EYFP-DNA conjugates enable the creation of precise calibration standards

  • These structures provide defined intermark separations (100-160 nm) for super-resolution microscopy verification

  • They demonstrate reproducible structural homogeneity and controllable labeling density

• Multi-color imaging approaches:

  • Combined use of EYFP with spectrally distinct fluorophores

  • Enables 2-color-dSTORM imaging with EYFP and organic dyes like Alexa 647

  • Expands capabilities for multiplexed protein detection

• Novel purification strategies:

  • Fluorescence-assisted protein purification using the chemical stability of hfYFP

  • Enables visualization of all steps of denaturing affinity chromatography using ultraviolet or blue light

  • Simplifies tracking of protein purification processes